MC4R agonist for obesity in young children scores high in phase III trial
The melanocortin-4 receptor (MC4R) agonist setmelanotide demonstrates efficacy in the management of obesity in children younger than 6 years, according to the results of a phase III trial.
MC4R agonist for obesity in young children scores high in phase III trial
20 Feb 2025
